Page last updated: 2024-10-16

carnitine and Alzheimer Disease

carnitine has been researched along with Alzheimer Disease in 32 studies

Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)

Research Excerpts

ExcerptRelevanceReference
"Acetyl-L-carnitine (ALCAR) is a drug currently under investigation for Alzheimer disease (AD) therapy."7.69Acetyl-L-carnitine in Alzheimer disease: a short-term study on CSF neurotransmitters and neuropeptides. ( Angelucci, L; Bonamini, M; Bruno, G; Cesarino, F; Grassini, P; Lenzi, GL; Patacchioli, FR; Scaccianoce, S; Sorrentino, E, 1995)
"The acute effects of intravenously administered L-acetylcarnitine (LAC) were evaluated with single-photon emission computed tomography (SPECT) and 99mTc-hexamethylpropyleneamine oxime in 30 demented patients (21 with a clinical diagnosis of Alzheimer's dementia and 9 with mixed-type dementia)."7.67Single-photon emission computed tomography studies with 99mTc-hexamethylpropyleneamine oxime in dementia: effects of acute administration of L-acetylcarnitine. ( Battistin, L; Borsato, N; Calvani, M; Da Col, C; Dam, M; Ferlin, G; Perlotto, N; Pizzolato, G; Saitta, B, 1989)
"Twenty-nine patients with probable Alzheimer's disease, 18 with mild cognitive impairment of the amnestic type, 24 with subjective memory complaint and 46 healthy subjects were enrolled in the study, and the levels of carnitine and acyl-carnitines were measured by tandem mass spectrometry."5.43Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer's Dementia. ( Angiolillo, A; Corbi, G; Corso, G; Cristofano, A; Di Costanzo, A; Intrieri, M; La Marca, G; Russo, C; Sapere, N; Scapagnini, G; Vitale, M, 2016)
"Acetyl-L-carnitine (ALCAR) is a drug currently under investigation for Alzheimer disease (AD) therapy."3.69Acetyl-L-carnitine in Alzheimer disease: a short-term study on CSF neurotransmitters and neuropeptides. ( Angelucci, L; Bonamini, M; Bruno, G; Cesarino, F; Grassini, P; Lenzi, GL; Patacchioli, FR; Scaccianoce, S; Sorrentino, E, 1995)
"The acute effects of intravenously administered L-acetylcarnitine (LAC) were evaluated with single-photon emission computed tomography (SPECT) and 99mTc-hexamethylpropyleneamine oxime in 30 demented patients (21 with a clinical diagnosis of Alzheimer's dementia and 9 with mixed-type dementia)."3.67Single-photon emission computed tomography studies with 99mTc-hexamethylpropyleneamine oxime in dementia: effects of acute administration of L-acetylcarnitine. ( Battistin, L; Borsato, N; Calvani, M; Da Col, C; Dam, M; Ferlin, G; Perlotto, N; Pizzolato, G; Saitta, B, 1989)
"L-carnitine (LC) plays a crucial role in the energetic metabolism of the cell."2.66Preventive Role of L-Carnitine and Balanced Diet in Alzheimer's Disease. ( Borzym-Kluczyk, M; Chojnowska, S; Kepka, A; Ochocinska, A; Skorupa, E; Stasiewicz-Jarocka, B; Waszkiewicz, N, 2020)
"L-Carnitine is an essential co-factor in the metabolism of lipids and consequently in the production of cellular energy."2.44[Physiological functions of carnitine and carnitine transporters in the central nervous system]. ( Inazu, M; Matsumiya, T, 2008)
"The pathogenesis of Alzheimer's disease (AD) is complex involving multiple contributing factors."1.43Alzheimer's disease-like pathology has transient effects on the brain and blood metabolome. ( Elliott, CT; Graham, SF; Green, BD; Hölscher, C; Kehoe, PG; McClean, PL; McGuinness, B; Nasaruddin, MB; Pan, X; Passmore, AP, 2016)
"Twenty-nine patients with probable Alzheimer's disease, 18 with mild cognitive impairment of the amnestic type, 24 with subjective memory complaint and 46 healthy subjects were enrolled in the study, and the levels of carnitine and acyl-carnitines were measured by tandem mass spectrometry."1.43Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer's Dementia. ( Angiolillo, A; Corbi, G; Corso, G; Cristofano, A; Di Costanzo, A; Intrieri, M; La Marca, G; Russo, C; Sapere, N; Scapagnini, G; Vitale, M, 2016)
"Increasing evidence suggest that Alzheimer's disease (AD) is a heterogeneous disorder that includes several subtypes with different etiology and progression."1.40Decreased cerebrospinal fluid levels of L-carnitine in non-apolipoprotein E4 carriers at early stages of Alzheimer's disease. ( Cedazo-Mínguez, Á; Cifuentes, A; Ibáñez, C; Lodeiro, M; Simó, C, 2014)
" Chronic administration of carnitine over time pre- and post-lesions seemed to partially ameliorate the cognitive deficits caused by the synaptic lesion."1.31Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine. ( Ando, S; Fukui, F; Iwamoto, M; Izumiyama, N; Kobayashi, S; Kon, K; Nakamura, H; Tadenuma, T; Takeda, Y; Waki, H; Watanabe, K, 2002)
"L-Carnitine was tested as a potential therapeutic agent, since it has been used to treat a variety of experimental metabolic encephalopathies."1.28Cultured cells as a screen for novel treatments of Alzheimer's disease. ( Baker, AC; Blass, JP; Malow, BA, 1989)

Research

Studies (32)

TimeframeStudies, this research(%)All Research%
pre-19905 (15.63)18.7374
1990's5 (15.63)18.2507
2000's3 (9.38)29.6817
2010's11 (34.38)24.3611
2020's8 (25.00)2.80

Authors

AuthorsStudies
Qutob, HMH1
Saad, RA1
Bali, H1
Osailan, A1
Jaber, J1
Alzahrani, E1
Alyami, J1
Elsayed, H1
Alserihi, R1
Shaikhomar, OA1
Divya, KM1
Savitha, DP1
Krishna, GA1
Dhanya, TM1
Mohanan, PV1
Shah, SF1
Jafry, AT1
Hussain, G1
Kazim, AH1
Ali, M1
Rivani, E1
Endraswari, PD1
Widodo, ADW1
Khalil, MR1
Guldberg, R1
Nørgård, BM1
Uldbjerg, N1
Wehberg, S1
Fowobaje, KR1
Mashood, LO1
Ekholuenetale, M1
Ibidoja, OJ1
Romagnoli, A1
D'Agostino, M1
Pavoni, E1
Ardiccioni, C1
Motta, S1
Crippa, P1
Biagetti, G1
Notarstefano, V1
Rexha, J1
Perta, N1
Barocci, S1
Costabile, BK1
Colasurdo, G1
Caucci, S1
Mencarelli, D1
Turchetti, C1
Farina, M1
Pierantoni, L1
La Teana, A1
Al Hadi, R1
Cicconardi, F1
Chinappi, M1
Trucchi, E1
Mancia, F1
Menzo, S1
Morozzo Della Rocca, B1
D'Annessa, I1
Di Marino, D1
Choya, A1
de Rivas, B1
Gutiérrez-Ortiz, JI1
López-Fonseca, R1
Xu, S1
Cheng, B1
Huang, Z1
Liu, T1
Li, Y1
Jiang, L1
Guo, W1
Xiong, J1
Amirazodi, M1
Daryanoosh, F1
Mehrabi, A1
Gaeini, A1
Koushkie Jahromi, M1
Salesi, M1
Zarifkar, AH1
Studeny, P1
Netukova, M1
Nemcokova, M1
Klimesova, YM1
Krizova, D1
Kang, H1
Tao, Y1
Zhang, Q1
Sha, D1
Chen, Y1
Yao, J1
Gao, Y1
Liu, J2
Ji, L1
Shi, P1
Shi, C1
Wu, YL1
Wright, AI1
M El-Metwaly, N1
A Katouah, H1
El-Desouky, MG1
El-Bindary, AA1
El-Bindary, MA1
Kostakis, ID1
Raptis, DA1
Davidson, BR1
Iype, S1
Nasralla, D1
Imber, C1
Sharma, D1
Pissanou, T1
Pollok, JM1
Hughes, AM1
Sanderson, E1
Morris, T1
Ayorech, Z1
Tesli, M1
Ask, H1
Reichborn-Kjennerud, T1
Andreassen, OA1
Magnus, P1
Helgeland, Ø1
Johansson, S1
Njølstad, P1
Davey Smith, G1
Havdahl, A1
Howe, LD1
Davies, NM1
Amrillah, T1
Prasetio, A1
Supandi, AR1
Sidiq, DH1
Putra, FS1
Nugroho, MA1
Salsabilla, Z1
Azmi, R1
Grammatikopoulos, P1
Bouloumis, T1
Steinhauer, S1
Mironov, VS2
Bazhenova, TA2
Manakin, YV2
Yagubskii, EB2
Yakushev, IA1
Gilmutdinov, IF1
Simonov, SV1
Lan, K1
Yang, H1
Zheng, J1
Hu, H1
Zhu, T1
Zou, X1
Hu, B1
Liu, H1
Olokede, O1
Wu, H1
Holtzapple, M1
Gungor, O1
Kose, M1
Ghaemi, R1
Acker, M1
Stosic, A1
Jacobs, R1
Selvaganapathy, PR1
Ludwig, N1
Yerneni, SS1
Azambuja, JH1
Pietrowska, M1
Widłak, P1
Hinck, CS1
Głuszko, A1
Szczepański, MJ1
Kärmer, T1
Kallinger, I1
Schulz, D1
Bauer, RJ1
Spanier, G1
Spoerl, S1
Meier, JK1
Ettl, T1
Razzo, BM1
Reichert, TE1
Hinck, AP1
Whiteside, TL1
Wei, ZL1
Juan, W1
Tong, D1
Juan, LX1
Sa, LY1
Jie, HFM1
Xiao, G1
Xiang, LG1
Jie, HM1
Xu, C1
Yu, DN1
Yao, ZX1
Bigdeli, F1
Gao, XM1
Cheng, X1
Li, JZ1
Zhang, JW1
Wang, W2
Guan, ZJ1
Bu, Y1
Liu, KG1
Morsali, A1
Das, R1
Paul, R1
Parui, A1
Shrotri, A1
Atzori, C1
Lomachenko, KA1
Singh, AK1
Mondal, J1
Peter, SC1
Florimbio, AR1
Coughlin, LN1
Bauermeister, JA1
Young, SD1
Zimmerman, MA1
Walton, MA1
Bonar, EE1
Demir, D1
Balci, AB1
Kahraman, N1
Sunbul, SA1
Gucu, A1
Seker, IB1
Badem, S1
Yuksel, A1
Ozyazicioglu, AF1
Goncu, MT1
Zhang, H1
Zhou, H1
Deng, Z1
Luo, L1
Ong, SP1
Wang, C1
Xin, H1
Whittingham, MS1
Zhou, G1
Maemura, R1
Wakamatsu, M1
Matsumoto, K1
Sakaguchi, H1
Yoshida, N1
Hama, A1
Yoshida, T1
Miwata, S1
Kitazawa, H1
Narita, K1
Kataoka, S1
Ichikawa, D1
Hamada, M1
Taniguchi, R1
Suzuki, K1
Kawashima, N1
Nishikawa, E1
Narita, A1
Okuno, Y1
Nishio, N1
Kato, K1
Kojima, S1
Morita, K1
Muramatsu, H1
Takahashi, Y1
Yirgu, A1
Mekonnen, Y1
Eyado, A1
Staropoli, A1
Vinale, F1
Zac, J1
Zac, S1
Pérez-Padilla, R1
Remigio-Luna, A1
Guzmán-Boulloud, N1
Gochicoa-Rangel, L1
Guzmán-Valderrábano, C1
Thirión-Romero, I1
Statsenko, ME1
Turkina, SV1
Barantsevich, ER1
Karakulova, YV1
Baranova, NS1
Morzhukhina, MV1
Wang, Q1
Gu, Y1
Chen, C1
Qiao, L1
Pan, F1
Song, C1
Canetto, SS1
Entilli, L1
Cerbo, I1
Cipolletta, S1
Wu, Y2
Zhu, P1
Jiang, Y1
Zhang, X1
Wang, Z1
Xie, B1
Song, T1
Zhang, F1
Luo, A1
Li, S1
Xiong, X1
Han, J1
Peng, X1
Li, M1
Huang, L1
Chen, Q1
Fang, W1
Hou, Y1
Zhu, Y2
Ye, J1
Liu, L1
Islam, MR1
Sanderson, P1
Johansen, MP1
Payne, TE1
Naidu, R1
Cao, J1
Yang, J2
Niu, X1
Liu, X1
Zhai, Y1
Qiang, C1
Niu, Y1
Li, Z1
Dong, N1
Wen, B1
Ouyang, Z1
Zhang, Y1
Li, J2
Zhao, M1
Zhao, J2
Morici, P1
Rizzato, C1
Ghelardi, E1
Rossolini, GM1
Lupetti, A1
Gözüküçük, R1
Cakiroglu, B1
He, X1
Li, R1
Zhao, D1
Zhang, L1
Ji, X1
Fan, X1
Chen, J1
Wang, Y1
Luo, Y1
Zheng, D1
Xie, L1
Sun, S1
Cai, Z1
Liu, Q1
Ma, K1
Sun, X1
Drinkwater, JJ1
Davis, TME1
Turner, AW1
Davis, WA1
Suzuki, Y1
Mizuta, Y1
Mikagi, A1
Misawa-Suzuki, T1
Tsuchido, Y1
Sugaya, T1
Hashimoto, T1
Ema, K1
Hayashita, T1
Chai, JF1
Raichur, S1
Khor, IW1
Torta, F1
Chew, WS1
Herr, DR1
Ching, J1
Kovalik, JP1
Khoo, CM1
Wenk, MR1
Tai, ES1
Sim, X1
Bolognino, I1
Giangregorio, N1
Pisani, L1
de Candia, M1
Purgatorio, R1
Tonazzi, A1
Altomare, CD1
Cellamare, S1
Catto, M1
van der Velpen, V1
Teav, T1
Gallart-Ayala, H1
Mehl, F1
Konz, I1
Clark, C1
Oikonomidi, A1
Peyratout, G1
Henry, H1
Delorenzi, M1
Ivanisevic, J1
Popp, J1
Huo, Z1
Yu, L1
Bennett, DA1
Maldonado, C1
Vázquez, M1
Fagiolino, P1
Kepka, A1
Ochocinska, A1
Borzym-Kluczyk, M1
Skorupa, E1
Stasiewicz-Jarocka, B1
Chojnowska, S1
Waszkiewicz, N1
Zhuang, Z1
Gao, M1
Yang, R1
Liu, Z1
Cao, W1
Huang, T1
Mota, SI1
Pita, I1
Águas, R1
Tagorti, S1
Virmani, A1
Pereira, FC1
Rego, AC1
Magi, S1
Preziuso, A1
Piccirillo, S1
Giampieri, F1
Cianciosi, D1
Orciani, M1
Amoroso, S1
Pochini, L1
Scalise, M1
Galluccio, M1
Indiveri, C1
Lodeiro, M1
Ibáñez, C1
Cifuentes, A1
Simó, C1
Cedazo-Mínguez, Á1
Mapstone, M1
Cheema, AK1
Fiandaca, MS1
Zhong, X1
Mhyre, TR1
MacArthur, LH1
Hall, WJ1
Fisher, SG1
Peterson, DR1
Haley, JM1
Nazar, MD1
Rich, SA1
Berlau, DJ1
Peltz, CB1
Tan, MT1
Kawas, CH1
Federoff, HJ1
Thomas, SC1
Alhasawi, A1
Appanna, VP1
Auger, C1
Appanna, VD1
Pan, X1
Nasaruddin, MB1
Elliott, CT1
McGuinness, B1
Passmore, AP1
Kehoe, PG1
Hölscher, C1
McClean, PL1
Graham, SF1
Green, BD1
Irwin, MH1
Moos, WH1
Faller, DV1
Steliou, K1
Pinkert, CA1
Cristofano, A1
Sapere, N1
La Marca, G1
Angiolillo, A1
Vitale, M1
Corbi, G1
Scapagnini, G1
Intrieri, M1
Russo, C1
Corso, G1
Di Costanzo, A1
Ciavardelli, D1
Piras, F1
Consalvo, A1
Rossi, C1
Zucchelli, M1
Di Ilio, C1
Frazzini, V1
Caltagirone, C1
Spalletta, G1
Sensi, SL1
Inazu, M1
Matsumiya, T1
Ahmed, HH1
Ando, S1
Kobayashi, S1
Waki, H1
Kon, K1
Fukui, F1
Tadenuma, T1
Iwamoto, M1
Takeda, Y1
Izumiyama, N1
Watanabe, K1
Nakamura, H1
Ames, BN1
Acierno, G1
Makar, TK1
Cooper, AJ1
Tofel-Grehl, B1
Thaler, HT1
Blass, JP2
Butterfield, DA1
Rangachari, A1
Bruno, G1
Scaccianoce, S1
Bonamini, M1
Patacchioli, FR1
Cesarino, F1
Grassini, P1
Sorrentino, E1
Angelucci, L1
Lenzi, GL1
Rubio, JC1
de Bustos, F1
Molina, JA1
Jiménez-Jiménez, FJ1
Benito-León, J1
Martín, MA1
Campos, Y1
Ortí-Pareja, M1
Cabrera-Valdivia, F1
Arenas, J1
Rai, G1
Wright, G1
Scott, L1
Beston, B1
Rest, J1
Exton-Smith, AN1
Malow, BA1
Baker, AC1
Gambi, D1
Onofrj, M1
Calvani, M2
Faricelli, A1
Del Re, ML1
Bazzano, S1
Cutarella, R1
Fulgente, T1
Colangelo, U1
Lucca, U1
Menasce, G1
Comelli, M1
Cizza, G1
Bressi, S1
Frattura, L1
Tiraboschi, P1
Spagnoli, A1
Battistin, L1
Pizzolato, G1
Dam, M1
Da Col, C1
Perlotto, N1
Saitta, B1
Borsato, N1
Ferlin, G1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease[NCT01320527]Phase 2135 participants (Actual)Interventional2008-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

7 reviews available for carnitine and Alzheimer Disease

ArticleYear
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
    Medicina clinica (English ed.), 2022, Dec-23, Volume: 159, Issue:12

    Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter

2022
Preventive Role of L-Carnitine and Balanced Diet in Alzheimer's Disease.
    Nutrients, 2020, Jul-03, Volume: 12, Issue:7

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carnitine; Diet, Healthy; Diet, Mediterranean; Dietary A

2020
OCTN cation transporters in health and disease: role as drug targets and assay development.
    Journal of biomolecular screening, 2013, Volume: 18, Issue:8

    Topics: Acetylcholine; Alzheimer Disease; Amino Acid Sequence; Animals; Biological Transport; Carnitine; Hum

2013
Brain metabolism and Alzheimer's disease: the prospect of a metabolite-based therapy.
    The journal of nutrition, health & aging, 2015, Volume: 19, Issue:1

    Topics: Acetoacetates; Adenosine Triphosphate; Aluminum; Alzheimer Disease; Astrocytes; Brain; Carnitine; Hu

2015
Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases.
    Drug development research, 2016, Volume: 77, Issue:3

    Topics: Alzheimer Disease; Antioxidants; Carnitine; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Hum

2016
[Physiological functions of carnitine and carnitine transporters in the central nervous system].
    Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 2008, Volume: 28, Issue:3

    Topics: Acetylcarnitine; Alzheimer Disease; Astrocytes; Brain; Carnitine; Choline; Energy Metabolism; Ketone

2008
Delaying the mitochondrial decay of aging with acetylcarnitine.
    Annals of the New York Academy of Sciences, 2004, Volume: 1033

    Topics: Acetylcarnitine; Aging; Alzheimer Disease; Animals; Brain; Carnitine; Dose-Response Relationship, Dr

2004

Trials

5 trials available for carnitine and Alzheimer Disease

ArticleYear
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
    Medicina clinica (English ed.), 2022, Dec-23, Volume: 159, Issue:12

    Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter

2022
[The use of 1-acetylcarnitine in (presenile and senile) Alzheimer's disease. Preliminary results].
    La Clinica terapeutica, 1983, Apr-30, Volume: 105, Issue:2

    Topics: Acetylcarnitine; Aged; Alzheimer Disease; Carnitine; Clinical Trials as Topic; Dementia; Double-Blin

1983
Cerebrospinal fluid carnitine levels in patients with Alzheimer's disease.
    Journal of the neurological sciences, 1998, Mar-05, Volume: 155, Issue:2

    Topics: Aged; Alzheimer Disease; Carnitine; Female; Humans; Male; Psychiatric Status Rating Scales; Referenc

1998
Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia.
    Current medical research and opinion, 1990, Volume: 11, Issue:10

    Topics: Acetylcarnitine; Activities of Daily Living; Aged; Alzheimer Disease; Carnitine; Double-Blind Method

1990
An example of a clinical trial in patients with Alzheimer's disease: some methodological issues.
    Progress in clinical and biological research, 1989, Volume: 317

    Topics: Acetylcarnitine; Aged; Alzheimer Disease; Carnitine; Clinical Trials as Topic; Double-Blind Method;

1989

Other Studies

21 other studies available for carnitine and Alzheimer Disease

ArticleYear
Associations with metabolites in Chinese suggest new metabolic roles in Alzheimer's and Parkinson's diseases.
    Human molecular genetics, 2020, 01-15, Volume: 29, Issue:2

    Topics: Alzheimer Disease; Asian People; ATP-Binding Cassette Transporters; Carnitine; China; DNA-Binding Pr

2020
A Prospective Repurposing of Dantrolene as a Multitarget Agent for Alzheimer's Disease.
    Molecules (Basel, Switzerland), 2019, Nov-25, Volume: 24, Issue:23

    Topics: Acetylcholinesterase; Alzheimer Disease; Calcium; Calcium Channel Blockers; Carnitine; Cell Line; Ch

2019
Systemic and central nervous system metabolic alterations in Alzheimer's disease.
    Alzheimer's research & therapy, 2019, 11-28, Volume: 11, Issue:1

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Brain; Carnitine; Cas

2019
Brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis.
    Neurobiology of aging, 2020, Volume: 86

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers; Brain; Carnitine; Cognition; Cohort Studies;

2020
Potential Therapeutic Role of Carnitine and Acetylcarnitine in Neurological Disorders.
    Current pharmaceutical design, 2020, Volume: 26, Issue:12

    Topics: Acetylcarnitine; Aged; Alzheimer Disease; Carnitine; Energy Metabolism; Humans; Oxidative Stress

2020
Causal relationships between gut metabolites and Alzheimer's disease: a bidirectional Mendelian randomization study.
    Neurobiology of aging, 2021, Volume: 100

    Topics: Alzheimer Disease; Betaine; Carnitine; Choline; Female; Gastrointestinal Microbiome; Genetic Predisp

2021
Mechanistic perspectives on differential mitochondrial-based neuroprotective effects of several carnitine forms in Alzheimer's disease in vitro model.
    Archives of toxicology, 2021, Volume: 95, Issue:8

    Topics: Acetylcarnitine; Alzheimer Disease; Animals; Apoptosis; Carnitine; Cells, Cultured; Female; Hippocam

2021
The Neuroprotective Effect of L-Carnitine against Glyceraldehyde-Induced Metabolic Impairment: Possible Implications in Alzheimer's Disease.
    Cells, 2021, 08-17, Volume: 10, Issue:8

    Topics: Adenosine Triphosphate; Alzheimer Disease; Animals; Carnitine; Cell Survival; Glyceraldehyde; Glycol

2021
Decreased cerebrospinal fluid levels of L-carnitine in non-apolipoprotein E4 carriers at early stages of Alzheimer's disease.
    Journal of Alzheimer's disease : JAD, 2014, Volume: 41, Issue:1

    Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E4; Arginine; Biomarkers; Carnitine;

2014
Plasma phospholipids identify antecedent memory impairment in older adults.
    Nature medicine, 2014, Volume: 20, Issue:4

    Topics: Aged; Alzheimer Disease; Asparagine; Biomarkers; Carnitine; Cognitive Dysfunction; Cohort Studies; D

2014
Alzheimer's disease-like pathology has transient effects on the brain and blood metabolome.
    Neurobiology of aging, 2016, Volume: 38

    Topics: Aging; Alzheimer Disease; Amino Acids, Branched-Chain; Amino Acids, Essential; Animals; Biogenic Pol

2016
Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer's Dementia.
    PloS one, 2016, Volume: 11, Issue:5

    Topics: Aged; Alzheimer Disease; Analysis of Variance; Biomarkers; Body Mass Index; Calibration; Carnitine;

2016
Medium-chain plasma acylcarnitines, ketone levels, cognition, and gray matter volumes in healthy elderly, mildly cognitively impaired, or Alzheimer's disease subjects.
    Neurobiology of aging, 2016, Volume: 43

    Topics: Aged; Aging; Alzheimer Disease; Carnitine; Cognition; Cognitive Dysfunction; Cohort Studies; Female;

2016
Modulatory effects of vitamin E, acetyl-L-carnitine and α-lipoic acid on new potential biomarkers for Alzheimer's disease in rat model.
    Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, 2012, Volume: 64, Issue:6

    Topics: Alzheimer Disease; Animals; Antioxidants; Biomarkers; Brain; Carnitine; Cholinesterase Inhibitors; D

2012
Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine.
    Journal of neuroscience research, 2002, Nov-01, Volume: 70, Issue:3

    Topics: Aging; Alzheimer Disease; Animals; Botulinum Toxins, Type A; Brain-Derived Neurotrophic Factor; Carn

2002
Carnitine, carnitine acetyltransferase, and glutathione in Alzheimer brain.
    Neurochemical research, 1995, Volume: 20, Issue:6

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Autopsy; Brain; Brain Chemistry; Carnitine; Carnitine O-

1995
Acetylcarnitine increases membrane cytoskeletal protein-protein interactions.
    Life sciences, 1993, Volume: 52, Issue:3

    Topics: Acetylcarnitine; Alzheimer Disease; Carnitine; Cytoskeletal Proteins; Electron Spin Resonance Spectr

1993
Acetyl-L-carnitine in Alzheimer disease: a short-term study on CSF neurotransmitters and neuropeptides.
    Alzheimer disease and associated disorders, 1995,Fall, Volume: 9, Issue:3

    Topics: Aged; Alzheimer Disease; Carnitine; Dopamine; Female; Humans; Male; Middle Aged; Neurotransmitter Ag

1995
Cultured cells as a screen for novel treatments of Alzheimer's disease.
    Archives of neurology, 1989, Volume: 46, Issue:11

    Topics: Alzheimer Disease; Carnitine; Cells, Cultured; Cyclic AMP; Fibroblasts; Humans; Hydrogen-Ion Concent

1989
Neurophysiological studies of L-acetylcarnitine administration in man.
    Drugs under experimental and clinical research, 1989, Volume: 15, Issue:9

    Topics: Acetylcarnitine; Adult; Aged; Alcoholic Intoxication; Alzheimer Disease; Carnitine; Electroencephalo

1989
Single-photon emission computed tomography studies with 99mTc-hexamethylpropyleneamine oxime in dementia: effects of acute administration of L-acetylcarnitine.
    European neurology, 1989, Volume: 29, Issue:5

    Topics: Acetylcarnitine; Aged; Alzheimer Disease; Carnitine; Dementia; Female; Humans; Injections, Intraveno

1989